Overview

Long-term Extension From RCC Phase II (11515)

Status:
Completed
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
Extension to study 11515 (NCT00661375) which was a multicenter study of sorafenib in patients with renal cell carcinoma (RCC).
Phase:
Phase 2
Details
Lead Sponsor:
Bayer
Treatments:
Niacinamide
Sorafenib